Akero Therapeutics, Inc.

NasdaqGS:AKRO Stock Report

Market Cap: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Akero Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:AKRO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 Sep 25SellUS$23,790Timothy RolphIndividual553US$43.02
11 Sep 25SellUS$28,350Catriona YaleIndividual659US$43.02
11 Sep 25SellUS$77,264Andrew ChengIndividual1,796US$43.02
11 Sep 25SellUS$28,350William WhiteIndividual659US$43.02
11 Sep 25SellUS$25,210Jonathan YoungIndividual586US$43.02
18 Jun 25SellUS$79,683Jonathan YoungIndividual1,453US$54.84
18 Jun 25SellUS$89,609William WhiteIndividual1,634US$54.84
18 Jun 25SellUS$61,914Timothy RolphIndividual1,129US$54.84
18 Jun 25SellUS$46,504Scott GangloffIndividual848US$54.84
18 Jun 25SellUS$363,041Andrew ChengIndividual6,620US$54.84
10 Jun 25SellUS$134,605Jonathan YoungIndividual2,493US$53.99
10 Jun 25SellUS$49,625Patrick LamyIndividual919US$54.00
10 Jun 25SellUS$151,351Catriona YaleIndividual2,803US$54.00
10 Jun 25SellUS$151,402William WhiteIndividual2,804US$54.00
10 Jun 25SellUS$127,323Timothy RolphIndividual2,358US$54.00
10 Jun 25SellUS$423,151Andrew ChengIndividual7,837US$53.99

Insider Trading Volume

Insider Buying: AKRO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AKRO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,155,1341.23%
Hedge Funds5,477,5615.84%
VC/PE Firms5,733,9896.12%
Institutions81,363,29086.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.

Top Shareholders

Top 25 shareholders own 81.07% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.63%
Janus Henderson Group plc
6,280,305US$342.6m-6.8%0.12%
6.97%
General Atlantic Service Company, L.P.
5,733,989US$312.8m0%5.98%
6.93%
BlackRock, Inc.
5,702,634US$311.1m-1.33%no data
6.65%
RTW Investments, LP
5,477,561US$298.8m0%2.99%
5.5%
The Vanguard Group, Inc.
4,526,920US$246.9m-0.06%no data
5.16%
Wellington Management Group LLP
4,251,861US$231.9m24.7%0.03%
4.86%
Deep Track Capital, LP
4,000,978US$218.3m31.5%4.07%
4.8%
Avoro Capital Advisors LLC
3,955,555US$215.8m13%2.32%
4.63%
T. Rowe Price Group, Inc.
3,810,076US$207.8m-15.5%0.02%
4.15%
State Street Global Advisors, Inc.
3,414,306US$186.3m24.4%0.01%
2.9%
Bellevue Asset Management AG
2,389,314US$130.3m20.4%1.63%
2.17%
Geode Capital Management, LLC
1,785,586US$97.4m3.67%0.01%
2.05%
AllianceBernstein L.P.
1,689,629US$92.2m9.99%0.03%
2.02%
Point72 Asset Management, L.P.
1,667,032US$90.9m-38.5%0.15%
1.89%
Alkeon Capital Management, LLC
1,552,001US$84.7m0%0.44%
1.54%
Bank of America Corporation
1,270,341US$69.3m-1.96%0.02%
1.48%
Marshall Wace LLP
1,217,044US$66.4m-14.2%0.08%
1.46%
Logos Global Management, L.P.
1,200,000US$65.5m0%4.73%
1.38%
Perceptive Advisors LLC
1,135,766US$62.0m24%1.32%
1.31%
FMR LLC
1,079,122US$58.9m15.9%no data
1.29%
Polar Capital Holdings Plc
1,058,776US$57.8m0%0.16%
1.28%
Holocene Advisors, LP
1,055,186US$57.6m-1.9%0.13%
1.13%
Pictet Asset Management Limited
926,441US$50.5m-6.1%0.03%
0.98%
Dimensional Fund Advisors LP
810,568US$44.2m41.3%0.01%
0.91%
Redmile Group, LLC
747,818US$40.8m-3.42%2.64%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/08 05:22
End of Day Share Price 2025/12/08 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akero Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Citi ResearchCitigroup Inc